TY - JOUR
T1 - Biomarkers
AU - Rodda, Joanne
AU - Kuchenbecker, Lindsey A.
AU - Borelli, Wyllians Vendramini
AU - DeMarco, Mari L.
AU - Cawston, Erin E.
AU - Chabrashvili, Tinatin
AU - Budelier, Melissa M.
AU - Duran-Aniotz, Claudia
AU - Udeh-Momoh, Chinedu T.
AU - Anderson, Leyla
AU - Mielke, Michelle M.
AU - Pereira, Ana C.
AU - Algeciras-Schimnich, Alicia
AU - Keshavan, Ashvini
AU - Castilhos, Raphael Machado
N1 - Publisher Copyright:
© 2025 The Alzheimer's Association. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2025/12/1
Y1 - 2025/12/1
N2 - BACKGROUND: Clinicians' views on clinical readiness of Alzheimer's disease (AD) blood biomarkers (BBM) are not well understood. METHOD: The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment Biofluid-Based Biomarkers Professional Interest Area conducted a survey to elicit clinician opinions on AD BBM implementation, including contexts of use, assay selection, reporting and result interpretation. RESULT: Clinician respondents (n = 212) practiced in Europe (56%), North America (24%), Caribbean and Central or South America (11%) and other continents (9%). Most respondents were medical doctors (80%) practicing in secondary or tertiary care (88%) (Table 1). For 56% of respondents, CSF AD biomarkers or amyloid PET were accessible, but 48% agreed and 52% disagreed with implementation of AD BBM in any clinical context (Table 2). Respondents emphasized the need for data from diverse populations and educational resources to support test interpretation. CONCLUSION: Surveyed clinicians generally agreed with published appropriate use recommendations but were divided on AD BBM readiness for clinical use.
AB - BACKGROUND: Clinicians' views on clinical readiness of Alzheimer's disease (AD) blood biomarkers (BBM) are not well understood. METHOD: The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment Biofluid-Based Biomarkers Professional Interest Area conducted a survey to elicit clinician opinions on AD BBM implementation, including contexts of use, assay selection, reporting and result interpretation. RESULT: Clinician respondents (n = 212) practiced in Europe (56%), North America (24%), Caribbean and Central or South America (11%) and other continents (9%). Most respondents were medical doctors (80%) practicing in secondary or tertiary care (88%) (Table 1). For 56% of respondents, CSF AD biomarkers or amyloid PET were accessible, but 48% agreed and 52% disagreed with implementation of AD BBM in any clinical context (Table 2). Respondents emphasized the need for data from diverse populations and educational resources to support test interpretation. CONCLUSION: Surveyed clinicians generally agreed with published appropriate use recommendations but were divided on AD BBM readiness for clinical use.
UR - https://www.scopus.com/pages/publications/105025836678
U2 - 10.1002/alz70856_100267
DO - 10.1002/alz70856_100267
M3 - Article
C2 - 41446983
AN - SCOPUS:105025836678
SN - 1552-5260
VL - 21
SP - e100267
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
ER -
